Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective

Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Int J Mol Sci
Huvudupphovsmän: Lavacchi, Daniele, Pellegrini, Elisa, Palmieri, Valeria Emma, Doni, Laura, Mela, Marinella Micol, Di Maida, Fabrizio, Amedei, Amedeo, Pillozzi, Serena, Carini, Marco, Antonuzzo, Lorenzo
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2020
Ämnen:
Review
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7369721/
https://ncbi.nlm.nih.gov/pubmed/32630154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21134691
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk